Skip to main content

Advertisement

SpringerLink
Log in

Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Introduction

Of the inherited thrombophilias, the Factor V Leiden (FVL) and the prothrombin mutant (FII G20210A) are associated with increased risk of venous thromboembolism (VTE). The C677T mutation of the methylenetetrahydrofolate reductase gene, which may lead to hyperhomocysteinemia, is also considered a risk factor for VTE in some studies. However, the frequency of these genetic risk factors may vary significantly among different populations.

Material and methods

The FVL, FII G20210A and C677T mutations were investigated by PCR-RFLP in 275 young VTE Brazilian patients as well as in 324 biologically unrelated individuals selected to compose the control group.

Results

The C677T mutation in the MTHFR gene was detected in 135 (49.1%) patients, of which 117 (42.5%) were identified as heterozygous and 18 (6.5%) as homozygous. The G20210A mutation was detected in 14 (5.1%) patients in heterozygosis. In both cases, no significant difference was observed when these results were compared to the frequencies observed in the control group. FVL was detected in heterozygosis in 19 (6.9%) patients, corresponding to a significantly increased frequency when compared to that observed for the control group (1.2%) (OR 5.9; 95% CI 2.08–16.79; p < 0.001).

Conclusions

The data indicated that FVL is significantly associated with VTE among young Brazilian patients, but also supported previous evidence that VTE is a multi-factorial disease, resulting from the interaction of genetic and acquired risk factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Collins R, Scrimgeour A, Yusuf S et al (1988) Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318:1162–1173

    Article  PubMed  CAS  Google Scholar 

  2. Clarke-Pearson DL, DeLong ER, Synan IS et al (1987) Variables associated with postoperative deep venous thrombosis: a prospective study of 411 gynecology patients and creation of a prognostic model. Obstet Gynecol 69:146–150

    PubMed  CAS  Google Scholar 

  3. Samama MM (1993) Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice: the SIRIUS study. Thromb Haemost 69:763

    Google Scholar 

  4. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596

    Article  PubMed  CAS  Google Scholar 

  5. Rosendaal FR (1999) Venous thrombosis: prevalence and interaction of risk factors. Haemostasis Suppl S1:1–9

    Article  Google Scholar 

  6. Dahlbaeck B, Carlsson M, Svensson PJ (1993) Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90:1004–1008

    Article  Google Scholar 

  7. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503–1506

    Article  PubMed  CAS  Google Scholar 

  8. Bertina RM, Koeleman BPC, Koster T et al (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64–67

    Article  PubMed  CAS  Google Scholar 

  9. Poort SW, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703

    PubMed  CAS  Google Scholar 

  10. Frosst P, Blom HJ, Milos R et al (1995) A candidate risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111–113

    Article  PubMed  CAS  Google Scholar 

  11. Undas A, Domagala B, Jankowski M, Szczeklik A (1999) Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. Thromb Res 95:281–288

    Article  PubMed  CAS  Google Scholar 

  12. Franco RF, Santos SEB, Elion J, Tavella MH, Zago MA (1998) The prevalence of the G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in different human populations. Acta Haematol 100:9–12

    Article  PubMed  CAS  Google Scholar 

  13. Rosendaal FR, Doggen CJ, Zivelin A et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706–708

    PubMed  CAS  Google Scholar 

  14. Rodrigues CA, Rocha LKA, Morelli VM, Franco RF, Lourenço DM (2004) Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost 2:1211–1212

    Article  PubMed  CAS  Google Scholar 

  15. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SDJ (2003) Color and genomic ancestry in Brazilians. PNAS 100:177–182

    Article  PubMed  CAS  Google Scholar 

  16. Huber S, Mcmaster KJ, Voelkerding KV (2000) Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A. J Mol Diagn 2:153–157

    PubMed  CAS  Google Scholar 

  17. Dean AG, Dean JA (1997) Coulombier, D. Epi Info, version 6.04: a word processing database and statistics program for epidemiology on microcomputers. Centre of Disease Control and Prevention, Atlanta

    Google Scholar 

  18. Rosendaal FR, Sicovick DS, Schwartz SM et al (1999) Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89:2817–2821

    Google Scholar 

  19. Salomon O, Steinberg DM, Zivelin A et al (1999) Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 19: 511–518

    PubMed  CAS  Google Scholar 

  20. Simioni P, Tormene D, Prandoni P et al (2002) Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 99:1938–1942

    Article  PubMed  CAS  Google Scholar 

  21. Sabino AP, Ribeiro DD, Carvalho MG, Cardoso J, Dusse LMS, Fernandes AP (2006) Factor V Leiden and increased risk for arterial thrombotic disease in young Brazilian patients. Blood Coagul Fibrinolysis 17:271–275

    Article  CAS  Google Scholar 

  22. Voetsch B, Damasceno BP, Camargo EC et al (2000) Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 83:229–233

    PubMed  CAS  Google Scholar 

  23. Eichinger S, Pabinger I, Stumpflen A et al (1997) The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 77:624–628

    PubMed  CAS  Google Scholar 

  24. Eichinger S, Weltermann A, Mannhalter C et al (2002) The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 162(20):2357–2360

    Article  PubMed  Google Scholar 

  25. De Stefano V, Martinelli I, Mannucci PM et al (1999) The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341:801–806

    Article  PubMed  Google Scholar 

  26. den Heijer M, Willems HP, Blom HJ (2007) Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109:139–144

    Article  CAS  Google Scholar 

  27. Cattaneo M, Chantarangkul V, Taioli E, Santos JH, Tagliabue L (1999) The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thromb Res 93:1–8

    Article  PubMed  CAS  Google Scholar 

  28. De Stefano V, Rossi E, Paciaroni K et al (2003) Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene. Haematologica 8:61–66

    Google Scholar 

  29. Bernstein D, Coupey S, Schonberg SK (1986) Pulmonary embolism in adolescents. Am J Dis Child 140:667–671

    PubMed  CAS  Google Scholar 

  30. Wu O, Robertson L, Langhorne P et al (2005) Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 94:17–25

    PubMed  CAS  Google Scholar 

  31. Mohllajee AP, Curtis KM, Martins SL, Peterson HB (2006) Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 73:166–178

    Article  PubMed  CAS  Google Scholar 

  32. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP (2001) Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 86:12–23

    Google Scholar 

  33. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP (2002) Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 22:201–210

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work received financial support from the CNPq, CAPES and FAPEMIG and from the Program “Redes Cooperativas de Pesquisa de Minas Gerais” (RECOPE-MG—REC—32-082/99).

Author information

Authors and Affiliations

  1. Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antônio Carlos, 6627, 31270-901, Belo Horizonte, MG, Brazil

    Adriano de Paula Sabino, Daniela Amorim Melgaço Guimarães, Sabrina Guimarães Paiva, Luci Maria Sant’Ana Dusse, Maria das Graças Carvalho & Ana Paula Fernandes

  2. Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

    Daniel Dias Ribeiro

Authors
  1. Adriano de Paula Sabino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniela Amorim Melgaço Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Dias Ribeiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabrina Guimarães Paiva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luci Maria Sant’Ana Dusse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria das Graças Carvalho
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana Paula Fernandes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ana Paula Fernandes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Paula Sabino, A., Guimarães, D.A.M., Ribeiro, D.D. et al. Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients. J Thromb Thrombolysis 24, 261–266 (2007). https://doi.org/10.1007/s11239-007-0024-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-007-0024-x

Keywords

Search

Navigation